Top

Published in:

01-11-2018 | Letter to Editor

JAK 1/2 Blockade in MDA5 Gain-of-Function

Authors: Kirsty E. McLellan, Neil Martin, Joyce E. Davidson, Nuno Cordeiro, Bridget D. Oates, Bénédicte Neven, Gillian I. Rice, Yanick J. Crow

Published in: Journal of Clinical Immunology | Issue 8/2018

Excerpt

To the Editor, …

Available only for authorised users

Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview. J Exp Med. 2016;213(12):2527–38.CrossRef

Hacohen Y, Zuberi S, Vincent A, Crow YJ, Cordeiro N. Neuromyelitis optica in a child with Aicardi-Goutières syndrome. Neurology. 2015;85(4):381–3.CrossRef

Rice, et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 2013;12(12):1159–69.CrossRef

Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011;86(12):1188–91.CrossRef

Frémond M-L, Rodero MP, Jeremiah N, Belot A, Jeziorski E, Duffy D, et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol. 2016;138(6):1752–5.CrossRef

Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041–52.CrossRef

Kothur K, Bandodkar S, Chu S, Wienholt L, Johnson A, Barclay P, et al. An open-label trial of JAK 1/2 blockade in progressiveIFIH1-associated neuroinflammation. Neurology. 2018;90(6):289–91.CrossRef

Title: JAK 1/2 Blockade in MDA5 Gain-of-Function
Authors: Kirsty E. McLellan
Neil Martin
Joyce E. Davidson
Nuno Cordeiro
Bridget D. Oates
Bénédicte Neven
Gillian I. Rice
Yanick J. Crow
Publication date: 01-11-2018
Publisher: Springer US
Published in: Journal of Clinical Immunology / Issue 8/2018
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-018-0563-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

JAK 1/2 Blockade in MDA5 Gain-of-Function

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2018

Home-Based Treatment with Immunoglobulins: an Evaluation from the Perspective of Patients and Healthcare Professionals

William T. Shearer MD, PhD in Memoriam

Warts and DADA2: a Mere Coincidence?

Clinical and Immunological Characterization of ICF Syndrome in Japan

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies

Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page